🇺🇸 FDA
Pipeline program

AXS-05 (dextromethorphan-bupropion)

AXS-05-AD-303

Phase 3 small_molecule completed

Quick answer

AXS-05 (dextromethorphan-bupropion) for Agitation in Patients With Dementia of the Alzheimer's Type is a Phase 3 program (small_molecule) at Axsome Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
Axsome Therapeutics
Indication
Agitation in Patients With Dementia of the Alzheimer's Type
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials